Compare Stocks: FRTX, UPC, LPCN, and PSTV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FRTX Fresh Tracks Therapeutics	$0.94	$0.94	$0.03 ▼ $1.03	$5.59M	0.54	2,709 shs	N/A
LPCN Lipocine	$2.27 +0.9%	$2.21	$1.81 ▼ $12.37	$18.72M	0.47	26,624 shs	10,398 shs
PSTV Plus Therapeutics	$2.33 -2.7%	$3.50	$2.90 ▼ $23.42	$26.64M	1.4	116,506 shs	79,988 shs
UPC Universe Pharmaceuticals	$4.36 +12.4%	$4.91	$2.00 ▼ $17.96	$21.91M	1.58	314,327 shs	143,360 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FRTX Fresh Tracks Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
LPCN Lipocine	0.00%	-7.35%	+10.19%	+0.44%	-24.33%
PSTV Plus Therapeutics	-2.72%	-15.61%	-37.16%	-53.59%	-79.87%
UPC Universe Pharmaceuticals	0.00%	+8.19%	-25.72%	+34.57%	+13.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FRTX Fresh Tracks Therapeutics	$0.94	$0.94	$0.03 ▼ $1.03	$5.59M	0.54	2,709 shs	N/A
LPCN Lipocine	$2.27 +0.9%	$2.21	$1.81 ▼ $12.37	$18.72M	0.47	26,624 shs	10,398 shs
PSTV Plus Therapeutics	$2.33 -2.7%	$3.50	$2.90 ▼ $23.42	$26.64M	1.4	116,506 shs	79,988 shs
UPC Universe Pharmaceuticals	$4.36 +12.4%	$4.91	$2.00 ▼ $17.96	$21.91M	1.58	314,327 shs	143,360 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FRTX Fresh Tracks Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
LPCN Lipocine	0.00%	-7.35%	+10.19%	+0.44%	-24.33%
PSTV Plus Therapeutics	-2.72%	-15.61%	-37.16%	-53.59%	-79.87%
UPC Universe Pharmaceuticals	0.00%	+8.19%	-25.72%	+34.57%	+13.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FRTX Fresh Tracks Therapeutics	0.00	N/A	N/A	N/A
LPCN Lipocine	1.50	Reduce	$15.00	560.79% Upside
PSTV Plus Therapeutics	2.33	Hold	$51.75	2,125.81% Upside
UPC Universe Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest FRTX, UPC, LPCN, and PSTV Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/3/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	PSTV Plus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/18/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FRTX Fresh Tracks Therapeutics	$10.06M	0.56	N/A	N/A	$1.66 per share	0.56
LPCN Lipocine	$1.57M	11.92	N/A	N/A	$2.61 per share	0.87
PSTV Plus Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A
UPC Universe Pharmaceuticals	$17.86M	1.23	N/A	N/A	$99.64 per share	0.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FRTX Fresh Tracks Therapeutics	-$5.69M	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	-$9.63M	-$1.79	N/A	N/A	N/A	-755.39%	-64.75%	-57.62%	11/5/2026 (Estimated)
PSTV Plus Therapeutics	-$22.39M	-$2.30	N/A	N/A	N/A	-230.24%	-198.48%	-73.13%	N/A
UPC Universe Pharmaceuticals	-$3.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest FRTX, UPC, LPCN, and PSTV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	PSTV Plus Therapeutics	-$0.88	-$1.31	-$0.43	-$1.31	$1.11 million	$0.41 million
8/4/2026	Q2 2026	LPCN Lipocine	-$0.40	-$0.32	+$0.08	-$0.32	$0.21 million	$0.19 million
7/29/2026	Q2 2026	UPC Universe Pharmaceuticals	N/A	-$1.38	N/A	-$1.38	N/A	$4.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FRTX Fresh Tracks Therapeutics	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
PSTV Plus Therapeutics	N/A	N/A	N/A	N/A	N/A
UPC Universe Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FRTX Fresh Tracks Therapeutics	N/A	N/A	N/A
LPCN Lipocine	N/A	11.48	11.48
PSTV Plus Therapeutics	N/A	2.27	2.27
UPC Universe Pharmaceuticals	0.04	4.05	3.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FRTX Fresh Tracks Therapeutics	25.04%
LPCN Lipocine	9.11%
PSTV Plus Therapeutics	3.28%
UPC Universe Pharmaceuticals	0.18%

Insider Ownership

Company	Insider Ownership
FRTX Fresh Tracks Therapeutics	0.23%
LPCN Lipocine	4.69%
PSTV Plus Therapeutics	2.50%
UPC Universe Pharmaceuticals	57.38%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FRTX Fresh Tracks Therapeutics	20	5.97 million	5.96 million	Not Optionable
LPCN Lipocine	10	8.24 million	7.86 million	No Data
PSTV Plus Therapeutics	20	6.88 million	6.71 million	Not Optionable
UPC Universe Pharmaceuticals	220	5.02 million	2.14 million	N/A

FRTX, UPC, LPCN, and PSTV Headlines

Recent News About These Companies

Universe Pharmaceuticals shares rise 22.6% premarket with no new catalyst identified

September 2, 2026 | msn.com

Universe Pharmaceuticals (UPC) stock soars over 38% after-hours: Here's what's going on

September 2, 2026 | msn.com

Universe Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:UPC

July 18, 2026 | benzinga.com

Universe Pharmaceuticals INC - Ordinary Shares - Class A

July 17, 2026 | money.usnews.com

Universe Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:UPC | Benzinga

June 29, 2026 | benzinga.com

4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones

June 29, 2026 | markets.businessinsider.com

China's Universe Pharmaceuticals (NASDAQ: UPC) Makes Nasdaq Top Gainer List on Acquisition News

June 29, 2026 | investorideas.comI

Universe Pharmaceuticals INC.: Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

June 27, 2026 | finanznachrichten.de

Universe Pharmaceuticals Inc

June 26, 2026 | fool.com

UPC stock surges 288% after hours — what’s driving the rally?

June 26, 2026 | msn.com

Universe Pharmaceuticals to acquire Best Praise for $10.75M

June 26, 2026 | seekingalpha.com

Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

June 26, 2026 | globenewswire.com

Universe Pharmaceuticals Stock News

June 17, 2026 | benzinga.com

Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology

June 16, 2026 | businesswire.com

Universe Pharmaceuticals Incorporation Class A

April 29, 2026 | edition.cnn.com

Universe Pharmaceuticals (NASDAQ:UPC) Stock Price Down 2.4% â€“ Time to Sell?

April 25, 2026 | defenseworld.netD

Universe Pharmaceuticals Sets February 13 Effective Date for Dual-Class Share Structure

February 11, 2026 | tipranks.com

Universe Pharmaceuticals INC Implements Dual-Class Share Structure on Nasdaq Effective February 13, 2026

February 11, 2026 | quiverquant.comQ

Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure

February 11, 2026 | globenewswire.com

Universe Pharmaceuticals Inc trading resumes

October 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

FRTX, UPC, LPCN, and PSTV Company Descriptions

Fresh Tracks Therapeutics NASDAQ:FRTX

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Lipocine NASDAQ:LPCN

$2.27 +0.02 (+0.89%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.24 -0.02 (-1.10%)

As of 09/11/2026 04:10 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Plus Therapeutics NASDAQ:PSTV

$2.33 -0.07 (-2.72%)

As of 09/11/2026

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Universe Pharmaceuticals NASDAQ:UPC

$4.36 +0.48 (+12.37%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$4.45 +0.09 (+2.06%)

As of 09/11/2026 07:39 PM Eastern

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FRTX, UPC, LPCN, and PSTV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FRTX, UPC, LPCN, and PSTV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FRTX, UPC, LPCN, and PSTV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

FRTX, UPC, LPCN, and PSTV Company Descriptions

Fresh Tracks Therapeutics NASDAQ:FRTX

Lipocine NASDAQ:LPCN

Plus Therapeutics NASDAQ:PSTV

Universe Pharmaceuticals NASDAQ:UPC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FRTX, UPC, LPCN, and PSTV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FRTX, UPC, LPCN, and PSTV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FRTX, UPC, LPCN, and PSTV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

FRTX, UPC, LPCN, and PSTV Company Descriptions

Fresh Tracks Therapeutics NASDAQ:FRTX

Lipocine NASDAQ:LPCN

Plus Therapeutics NASDAQ:PSTV

Universe Pharmaceuticals NASDAQ:UPC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools